Original scientific paper

https://doi.org/10.5599/admet.4.1.275

Transport of six tyrosine kinase inhibitors: active or passive ?

Richard J. Honeywell ; Department of Medical oncology, VU university medical center, Amsterdam, The Netherlands
Sarina Hitzerd ; Department of Medical oncology, VU university medical center, Amsterdam, The Netherlands
Ietje Kathmann ; Department of Medical oncology, VU university medical center, Amsterdam, The Netherlands
Godefridus J. Peters orcid.org/0000-0002-5447-2877 ; Department of Medical oncology, VU university medical center, Amsterdam, The Netherlands

Abstract

Transport of erlotinib, gefitinib, sorafenib, sunitinib, dasatinib and crizotinib can be active or passive, which was studied by measuring uptake at low (4 °C; passive) and normal temperature (37 °C; active and passive) and by the use of specific organic cation transporter (OCT) inhibitors. Intracellular accumulation was determined using Caco-2 as monolayers, while for gut permeation we used differentiated Caco-2 as model for intestinal epithelium in the Transwell system. Sorafenib and crizotinib uptake are likely to be dependent on passive transport. Gefitinib, dasatinib and sunitinib uptake seem to be active. Erlotinib’s transport also seems to be active. This study suggests that hOCTs might be involved in the apical to basolateral transport of gefitinib and crizotinib. Overall it can be concluded that the accumulation and transport of these six TKIs are very different, despite the fact that they are all tyrosine kinase inhibitors.

Keywords

Tyrosine kinase; drug transport; erlorinib; gefitinib; sorafenib; sunitinib; dasatinib; crizotinib

Hrčak ID:

154843

URI

https://hrcak.srce.hr/154843

Publication date:

31.3.2016.

Visits: 1.979 *